about
Initial sequencing and comparative analysis of the mouse genomeElectronic health records: Implications for drug discoveryIdentification and initial characterization of 5000 expressed sequenced tags (ESTs) each from adult human normal and osteoarthritic cartilage cDNA librariesHuman disease-drug network based on genomic expression profilesSystematic drug repositioning based on clinical side-effectsHarnessing public domain data to discover and validate therapeutic targets.Evaluation of analytical methods for connectivity map data.Computational drug repositioning: from data to therapeutics.Gene Vector Analysis (Geneva): a unified method to detect differentially-regulated gene sets and similar microarray experimentsExon structure conservation despite low sequence similarity: a relic of dramatic events in evolution?Comparison of mouse and human genomes followed by experimental verification yields an estimated 1,019 additional genes.Systematic evaluation of connectivity map for disease indicationsA novel approach applying a chemical biology strategy in phenotypic screening reveals pathway-selective regulators of histone 3 K27 tri-methylation.A High-Content Imaging Screen for Cellular Regulators of β-Catenin Protein Abundance.Exploring the foundation of genomics: a northern blot reference set for the comparative analysis of transcript profiling technologies.A pathway-based view of human diseases and disease relationships.Literature mining in support of drug discovery.Computational identification of transcription factors involved in early cellular response to a stimulus.An assessment of gene prediction accuracy in large DNA sequences.Comparative gene prediction in human and mouse.Combined Analysis of Phenotypic and Target-Based Screening in Assay Networks.Reply to Rational drug repositioning by medical genetics.A global pathway crosstalk network.Inferring pathways from gene lists using a literature-derived network of biological relationships.Drug repositioning from the combined evaluation of phenotypic and target-based screening.Trial watch: Impact of genetically supported target selection on R&D productivity.Connecting genetics and gene expression data for target prioritisation and drug repositioning.Computational Drug Repositioning by Ranking and Integrating Multiple Data SourcesNovelty in the target landscape of the pharmaceutical industryUse of genome-wide association studies for drug repositioningScientific literature mining for drug discovery: a case study on obesityCan literature analysis identify innovation drivers in drug discovery?BET Inhibition Improves NASH and Liver FibrosisCould advances in representation learning in Artificial Intelligence provide the new paradigm for data integration in drug discovery?Pathway analysis of GWAS loci identifies novel drug targets and repurposing opportunities
P50
Q22122521-99952BB0-4698-49F4-BB3A-3C516F8BDAC5Q27010361-92CAC6F8-8779-4167-AF42-ED8A354564EAQ28198039-083DD119-4F08-4C47-97C3-06C82A5B58F3Q28475892-6087F76F-E0A6-43AA-BD6C-DC7A357E29CAQ28478506-BB94D16B-725C-4A25-896D-56BB29028337Q30491667-24D60EB1-5693-47FB-8FA6-A11B8BCDCC3BQ30591185-6E9F83DC-BE3C-4B4C-A874-9DB7E0D27F31Q30594820-9B51E93D-B409-4E8B-9275-A7C4E5154E83Q33362575-17045C69-B470-453D-8659-BC7A47E68712Q34082667-FC0B0BD4-5FD6-4BAA-BD38-4BDA286D3AAFQ34329481-5216B70F-FF3E-4131-B8DC-0C48201A6B0FQ34781421-52E6F90F-1DF2-4DEE-ADE2-002D7A3C349CQ35047789-DC9AC5C8-DA98-4683-A4B2-82F4238CC432Q35866247-D5942485-28D4-4F42-8165-7606C0465F58Q36748753-38A93198-4B24-4EE0-9744-DC3895B0F77CQ37073294-8D2D59D5-B90D-44AB-AF5D-7FE221025B6AQ37280361-7FE8661E-A933-4565-AFD6-9D51C76DB97EQ38322617-A3D5867D-BBE2-402D-8CAE-2F37DAE07412Q40414434-DC8D30A3-CB5A-4CF7-8ACE-CAAE1A90838BQ40610407-F48BCE8E-D878-4F2A-9FD4-CE88FEBAE991Q42644852-32228AD8-9AE2-474D-B9C3-0CE87EFF3614Q44602104-FA1A3A5A-297D-4659-B0DA-2A0CA6CB0C03Q45717175-FAD20D90-C0B6-476C-B574-C652F0C737BDQ48516373-624B21E1-71D6-4A2C-AD12-104132E9CAC2Q54493705-A6635532-9E7D-4417-B776-8CFD6CFA1DA0Q54637095-ABEDF904-8CA7-48AA-9418-E1979CA8DCBCQ55285352-77CE5743-D11B-40C1-AF23-1CEE14152F3EQ57338669-AD8C508F-D7FD-4948-8966-735A7EE94E8DQ57338670-61AF68E2-8CBF-4EE9-8FFE-14C05063C093Q57338671-9882F102-C08A-4626-8D65-68CA954AE4A8Q57338672-698A5ACC-708E-4AEC-ADCE-77CFACF87D8DQ57338674-7121D685-AB79-41AE-BEE0-331FAF16C400Q59333200-0B7234CB-2F16-44E7-AC16-4194CACACF9AQ62491303-9E8EF369-AD79-4AFD-8C2A-95F3AB051552Q92764192-A46B2B92-FE07-46E5-A0F6-99CBCA5A872C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Pankaj Agarwal
@ast
Pankaj Agarwal
@en
Pankaj Agarwal
@es
Pankaj Agarwal
@fr
Pankaj Agarwal
@nl
Pankaj Agarwal
@sl
type
label
Pankaj Agarwal
@ast
Pankaj Agarwal
@en
Pankaj Agarwal
@es
Pankaj Agarwal
@fr
Pankaj Agarwal
@nl
Pankaj Agarwal
@sl
prefLabel
Pankaj Agarwal
@ast
Pankaj Agarwal
@en
Pankaj Agarwal
@es
Pankaj Agarwal
@fr
Pankaj Agarwal
@nl
Pankaj Agarwal
@sl
P106
P1153
55574190709
P21
P2798
P31
P3835
pankaj-agarwal5
P496
0000-0002-4165-9990